Related Experiment Video
Updated: Feb 13, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Subsequent primary cancer risks for non-hereditary colorectal cancer survivors
Ye Kyaw Aung1, Mark A Jenkins1,2, Nancy N Baxter3
1Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC, 3010, Australia.
Background:
Colorectal cancer survivors have increased risks of subsequent primary cancers (SPCs), but most studies have included individuals with hereditary colorectal cancer syndromes. This study assessed SPC risks for colorectal cancer survivors without a known hereditary predisposition to colorectal cancer.
Methods:
We analyzed data from the Colon Cancer Family Registry Cohort, recruiting participants between 1998 and 2012 through population cancer registries in Australia, Canada and the United States, with follow-up every five years (until December 2022). Individuals with pathogenic germline mutations in APC, MUTYH, or DNA mismatch repair genes were excluded. Standardized incidence ratios (SIRs) were calculated by comparing observed cases with expected cases based on age-, sex-, country-, and calendar period-specific incidence rates.
Findings:
The study included 7202 (49.8% female) colorectal cancer survivors with a mean age at diagnosis of 55.1 (SD 11.5) years and a mean follow-up of 10.6 (SD 7.45) years. Overall, there was no evidence of increased SPC risk (SIR 1.04, 95% CI: 0.98-1.11). Elevated risks were observed for subsequent primary colorectal (SIR 1.34, 95% CI: 1.14-1.57), hematopoietic (SIR 2.49, 95% CI: 1.92-3.21), liver (SIR 2.25, 95% CI: 1.51-3.36), and thyroid (SIR 1.90, 95% CI: 1.20-3.02) cancer. Early-onset colorectal cancer cases (diagnosed before age 50) had increased SPC risks (SIR 1.43, 95% CI: 1.25-1.64) while those diagnosed at 50 and above did not (p < 0.001).
Interpretation:
In non-hereditary colorectal cancer survivors, overall SPC risks are not elevated, but early-onset cases have higher risks and therefore warrant targeted surveillance and follow-up.
Funding:
National Institutes of Health (U01 CA167551) and National Health and Medical Research Council (1194392).
Related Concept Videos
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

